Newlink Genetics Corporation

Genentech, Inc.

Lumos Pharma, Inc.

Hima Potturi

Firoz Jaipuri

Sanjeev Kumar

Jesse Waldo

Mario Mautino

Hong Zhuang

Lewis J Gazzard

Zhonghua Pei

Richard Pastor

Xingyu Lin

Brendan Parr

Po-Wai Yuen

Rohan V Mendonca

Guosheng Wu

Wendy Liu

Benjamin Douglas Sellers

Yanyan Chu

Xiaokai Li

Guoshen Wu

Roheeth Pavana

Powai Yuen

Venkata Velvadapu

Zuhui Zhang

Presently provided are inhibitors of TD02 and IDO1 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

TDO2 and IDO1 inhibitors

Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.

Salts and prodrugs of 1-methyl-d-tryptophan

Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

TDO2 Inhibitors

Salts and prodrugs of 1-methyl-D-tryptophan

Growing community of inventors

Ames, IA, United States of America

Hima Potturi